Patents Assigned to Beth Israel Deaconess Medical Center
  • Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • Patent number: 11497885
    Abstract: Apparatus and methods for producing narrow-band radiation in the green region of the visible spectrum are described. The narrow-band radiation may be used to aid subjects experiencing photophobia. In some cases, subjects may experience a reduction in pain (e.g., migraine photophobia) when using the narrow-band radiation.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 15, 2022
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 11499152
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 15, 2022
    Assignees: Beth Israel Deaconess Medical Center, Aalborg University
    Inventors: Pier Paolo Pandolfi, Riccardo Panella, Sakari Kauppinen, Andreas Petri
  • Publication number: 20220354499
    Abstract: Preferred embodiments relate to devices for performing a lymphovenous bypass procedure. A first ring is secured to tissue connected to at least one lymphatic channel of a patient and a second ring is attached to a vein of the patient. An end of the lymphatic channel that extends through the first ring is inserted into an open end of the vein and the rings are connected together to establish fluid flow from the lymphatic channel into the vein.
    Type: Application
    Filed: June 19, 2020
    Publication date: November 10, 2022
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dhruv Singhal, Kieran Singhal
  • Patent number: 11492403
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 8, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Patent number: 11491480
    Abstract: Filtration apparatuses, kits, and methods for rapid isolation of intact, viable mitochondria from tissues are described with mitochondria isolated by differential filtration through nylon mesh filters. Mitochondria can be isolated in less than 30 minutes using the filtration apparatuses, kits, and methods described.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: November 8, 2022
    Assignees: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: James D. McCully, Douglas B. Cowan, Christina A. Pacak, Sidney Levitsky
  • Publication number: 20220340952
    Abstract: Embodiments allow for rapid antimicrobial susceptibility testing (AST) at a low cost. Embodiments may use changes in the pixel intensity from reflected light to determine microorganism growth and antimicrobial resistance. Dilutions of an antimicrobial are added to a standard well plate or other array. A pathogen or other microorganism may be added to the dilutions in the well plate. The well plate may be incubated for a time period less than 3 hours. The well plate may then be imaged and the resulting image data may be analyzed. Wells where the microorganism is able to grow may appear darker than wells where the microorganism did not grow. Differences pixel intensity of the wells is used to determine the susceptibility or resistance of the microorganism to the antimicrobial. The image data may be used to determine the minimum inhibitory concentration (MIC), the lowest dilution concentration of antimicrobial that inhibits growth.
    Type: Application
    Filed: September 28, 2020
    Publication date: October 27, 2022
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: James E. Kirby, Ramy Arnaout, Kenneth P. Smith, Matthew Ware
  • Patent number: 11446487
    Abstract: System and methods for determining placement of a transducer array relative to a subject's head, which may be used in treating cancer in the subject, are provided. These techniques may include constructing, based on one or more images, a representation of the subject's head that includes information for a plurality of structures including one or more tumors positioned within the subject's brain. The representation of the subject's head may be used to calculate electric field propagation for one or more arrangements of a transducer array on a surface of the subject's head. These techniques may further include determining one or more rate of energy absorption distributions and/or one or more electric field distributions using the calculated electric field propagation for multiple arrangements of the transducer array. A rate of energy absorption distribution may indicate a rate of energy absorbed at the one or more tumors.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 20, 2022
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Eric Wong, Edwin Lok
  • Publication number: 20220288207
    Abstract: By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit protein targets that were previously regarded as undruggable. The compounds described herein comprise a photolabile group on PROTACs, enabling the degradation of protein targets in a spatiotemporally controlled manner By adding a photolabile caging group on ubiquitin recruiting moieties, light-inducible protein degradation was acheived. These opto-PROTACs display no activity in the dark, while restricted degradation can be induced at a specific time and rate by UVA-irradiation. Accordingly, these compounds provide light-controlled PROTACs and methods of using such compounds.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 15, 2022
    Applicants: Beth Israel Deaconess Medical Center, Inc., Icahn School of Medicine at Mount Sinai
    Inventors: Wenyi WEI, Jian JIN, Husnu Umit KANISKAN, He CHEN, Jing LIU
  • Patent number: 11439685
    Abstract: The present invention provides formulations for the treatment of fibrotic diseases and disorders. In some embodiments, the formulation comprises a microparticle that includes an antifibrotic.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: September 13, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Mark W. Grinstaff, William Blessing, Amanda Williamson, Jack Kirsch, Katherine Cook, Ara Nazarian, Edward K. Rodriguez
  • Patent number: 11434264
    Abstract: Ultrasensitive and quantitative assays for detecting toxins of Clostridium difficile, which may involve digital ELISA, are provided. Also provided herein are differential detection assays that allow for distinguishing toxin B of highly virulent Clostridium difficile strains from toxin B of less virulent strains.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 6, 2022
    Assignees: Quanterix Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nira Pollock, Ciaran Kelly, David C. Duffy, Linan Song, Mingwei Zhao
  • Patent number: 11415655
    Abstract: Some aspects of the present disclosure relate a method for magnetic resonance imaging, which can include acquiring, by applying an imaging pulse sequence, magnetic resonance data associated with a region of interest of a subject. The imaging pulse sequence can include a plurality of RF pulses configured to generate a desired image contrast, and an outer-volume suppression (OVS) module to attenuate the signal outside the region of interest. The method can further include reconstructing, from the acquired magnetic resonance data, a plurality of reduced field of view (rFOV) magnetic resonance images corresponding to the region of interest.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 16, 2022
    Assignees: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Michael Salerno, Yang Yang, Li Zhao, Xiao Chen
  • Publication number: 20220226481
    Abstract: Disclosed are bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 21, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Nathanael Gray, Inchul You, Tinghu Zhang, Eric Fischer, Katherine Donovan, Emily Erickson, Alex Toker
  • Publication number: 20220218260
    Abstract: Disclosed herein are example methods and systems for predicting efficacy of pacemakers or cardiac resynchronization therapy (CRT) devices prior to implantation in patients based on electrocardiogram (ECG) heterogeneity analysis. A method of determining or predicting efficacy of implanting a pacemaker or cardiac resynchronization therapy (CRT) device in a patient includes receiving a first set of electrocardiogram (ECG) signals associated with the patients heart from spatially separated leads, analyzing data from the first set of ECG signals, quantifying a spatio-temporal heterogeneity of the first set of ECG signals based on the analysis, and determining or predicting efficacy of implanting the pacemaker or cardiac re-synchronization therapy (CRT) device in the patient based on the quantified spatio-temporal heterogeneity.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 14, 2022
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Richard L. VERRIER, Bruce D. Nearing, Peter J. ZIMETBAUM
  • Patent number: 11384122
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
  • Patent number: 11366186
    Abstract: Systems and methods are provided for producing hyperpolarized materials for use during a magnetic resonance imaging (MRI) or nuclear magnetic resonance (NMR) process. The system and methods include the use of microfluidic and/or microreactor methods in one or more of the stages of parahydrogen production, enriched substrate production, and spin order transfer from the parahydrogen to a substrate.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 21, 2022
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David Alsop, Aaron Grant
  • Publication number: 20220185801
    Abstract: The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.
    Type: Application
    Filed: January 28, 2022
    Publication date: June 16, 2022
    Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark FEINBERG, Santosh A. KHEDKAR
  • Patent number: 11357742
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 14, 2022
    Assignees: X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
  • Publication number: 20220177422
    Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 9, 2022
    Applicants: The University of Chicago, The United States of America,as Represented by the Secretary, Department of Health and Human Servic, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Julian SOLWAY, Nickolai DULIN, Diane Luci, David MALONEY, Chan Young PARK, Jeffrey FREDBERG, David MCCORMICK, Ramaswamy KRISHNAN
  • Patent number: D957635
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: July 12, 2022
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: John Wixted